背景：当前的研究评估了疾病负担，医疗保健资源的利用，并分析了由于在迪拜诊断和治疗的乳腺癌（BC）患者中特别感兴趣的事件引起的成本负担，阿拉伯联合酋长国(UAE),在一般情况下以及在接受细胞周期蛋白依赖性激酶（CDK）4/6抑制剂治疗的患者亚组中。
方法：这项回顾性队列研究，使用来自迪拜现实世界数据库的保险电子索赔数据，于2014年1月1日至2021年9月30日进行。包括年龄≥18岁的女性患者，至少有1次BC诊断报告，并且在索引期内连续入选。
结果：总体而言，8,031例患者被诊断为BC（中位年龄：49.0岁），大多数（68.1％）在41-60岁年龄段。在索引后期间，BC特异性费用占BC患者总疾病负担的84%。住院费用(16,956.2美元)和药物费用(10,251.3美元)对不列颠哥伦比亚省特定费用有很大贡献。在CDK4/6抑制剂是治疗方案一部分的患者亚组中（n=174），CDK4/6抑制剂通常与芳香酶抑制剂（41.4％）和雌激素受体拮抗剂（17.9％）联合使用。在BC患者中，由于特殊关注事件（n=1,843）导致的医疗保健费用占总疾病费用负担的17％。
结论：该研究强调了BC患者的巨大成本负担，BC特定费用占总疾病费用负担的84%。尽管存在一些限制，例如研究人群主要由私人保险的外籍患者组成，并且在当前研究中仅评估直接医疗费用，大多数指示性成本已被纳入研究，通过仔细的病人选择和费用比较，如适用。这些发现可以指导关键的医疗保健利益相关者（付款人和提供者）采取旨在减少BC患者成本负担的未来政策措施。
BACKGROUND: The current study evaluated the disease burden, health care resource utilization and analyzed the cost burden due to events of special interest among patients with breast cancer (BC) diagnosed and treated in Dubai, United Arab Emirates (UAE), in general and in the subset of patients treated with cyclin-dependent kinase (CDK) 4/6 inhibitors.
METHODS: This retrospective cohort study, using insurance e-claims data from Dubai Real-World Database, was conducted from 01 January 2014 to 30 September 2021. Female patients aged ≥ 18 years with at least 1 diagnosis claim for BC and with continuous enrollment during the index period were included.
RESULTS: Overall, 8,031 patients were diagnosed with BC (median age: 49.0 years), with the majority (68.1%) being in 41-60-year age group. During the post-index period, BC-specific costs contributed to 84% of the overall disease burden among patients with BC. Inpatient costs (USD 16,956.2) and medication costs (USD 10,251.3) contributed significantly to BC-specific costs. In the subgroup of patients in whom CDK4/6 inhibitors were part of the treatment regimen (n = 174), CDK4/6 inhibitors were commonly prescribed in combination with aromatase inhibitors (41.4%) and estrogen receptor antagonists (17.9%). In patients with BC, health care costs due to events of special interest (n = 1,843) contributed to 17% of the overall disease cost burden.
CONCLUSIONS: The study highlights the significant cost burden among patients with BC, with BC-specific costs contributing to 84% of the overall disease cost burden. Despite few limitations such as study population predominantly comprising of privately insured expatriate patients and only direct healthcare costs being assessed in the current study, most indicative costs have been captured in the study, by careful patient selection and cost comparisons, as applicable. The findings can guide key health care stakeholders (payers and providers) on future policy measures aiming to reduce the cost burden among patients with BC.
PDF(Pubmed)